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Background: The purpose of this study is to image the effect of diabetes on expression of receptor for advanced
glycation endproducts (RAGE) in limb ischemia in live animals.
Methods: Male wild-type C57BL/6 mice were either made diabetic or left as control. Two months later, diabetic
and non-diabetic mice underwent left femoral artery ligation. The right leg served as lesion control. Five days later,
mice were injected with 15.1 ± 4.4 MBq 99mTc-anti-RAGE F(ab’)2 and 4 to 5 h later (blood pool clearance)
underwent SPECT/CT imaging. At the completion of imaging, mice were euthanized, hind limbs counted and
sectioned, and scans reconstructed. Regions of interest were drawn on serial transverse sections comprising the
hind limbs and activity in millicuries summed and divided by the injected dose (ID). Quantitative histology was
performed for RAGE staining and angiogenesis.
Results: Uptake of 99mTc-anti-RAGE F(ab')2 as %ID × 10
−3 was higher in the left (ischemic) limbs for the diabetic
mice (n = 8) compared to non-diabetic mice (n = 8) (1.20 ± 0.44% vs. 0.49 ± 0.40%; P = 0.0007) and corresponded
to less angiogenesis in the diabetic mice. Uptake was also higher in the right limbs of diabetic compared to non-
diabetic animals (0.82 ± 0.33% vs. 0.40 ± 0.14%; P = 0.0004).
Conclusions: These data show the feasibility of imaging and quantifying the effect of diabetes on RAGE expression
in limb ischemia.
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Peripheral artery disease (PAD) is a common condition
producing symptomatic ischemic leg pain with exertion
(claudication) and in diabetics can be a particularly ma-
lignant disease leading to rest pain and gangrene requir-
ing amputation. There are currently no effective drug
therapies for symptomatic PAD, leaving surgical revascu-
larization and interventional catheter-based approaches.
There is a wealth of published data from experimental
studies and a few clinical studies that provide evidence
to support the central role for receptor for advanced
glycation endproducts (RAGE) in the development and
progression of PAD in atherosclerosis and diabetes.* Correspondence: lj2129@columbia.edu
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in any medium, provided the original work is pRAGE is a 35 kDa polypeptide of the immunoglobulin
superfamily that is a multiligand receptor shown to be
an important mediator of inflammation in a variety of
conditions including atherosclerosis and the complica-
tions of diabetes [1-7]. RAGE is constitutively expressed
at low levels on smooth muscle cells and endothelial
cells in the vascular endothelium [3]. Increased expres-
sion of RAGE in the vascular wall occurs in response to
a number of stimuli including hyperlipidemia and hyper-
glycemia [3-6]. In the non-diabetic limb, in response to
tissue hypoxia, via the hypoxia-inducible factor-1 alpha
(HIF-1a) pathway, vascular endothelial growth factor
(VEGF) is released locally and stimulates angiogenesis
through multiple mechanisms that include increased
proliferation and decreased apoptosis of endothelial cells
and chemoattraction of monocytes into the ischemic tis-
sue [8,9]. In diabetes, this normally adaptive response toan Open Access article distributed under the terms of the Creative Commons
g/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction
roperly cited.
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major mechanistic role in this maladaptive response by
reducing VEGF mRNA and by inducing a defect in signal
transduction resulting in fewer monocytes in the tissue to
stimulate angiogenesis [10-12]. Experimental studies sup-
pressing RAGE ligands have shown improvement in an-
giogenic response to limb ischemia [13,14].
We have previously shown that molecular imaging using
a radionuclide probe targeting ανβ3 expression during
angiogenesis can detect the effect of diabetes to suppress
angiogenesis in mouse models of hind limb ischemia [15].
We have developed a radiolabeled murine monoclonal
antibody targeting RAGE for in vivo imaging of RAGE ex-
pression and have shown focal uptake of this probe in ath-
eroma in apolipoprotein E-deficient (apoE−/−) mice both
with and without diabetes [16]. In this current study, we
extend our previous work to investigate the hypothesis
that RAGE-directed molecular imaging can detect the ef-
fect of diabetes on RAGE expression in a murine model of
hind limb ischemia.
Methods
All animal experiments were performed in accordance
with the approval of the Institutional Animal Care and
Use Committee of Columbia University. Male wild-type
(WT) C57BL/6 mice (n = 20) were obtained (Jackson La-
boratories, Bar Harbor, ME, USA). Diabetic mice (n = 8)
and non-diabetic mice (n = 8) were injected with radio-
labeled anti-RAGE F(ab’)2. Probe control non-diabetic
mice (n = 4) were injected with non-immune IgG F(ab’)2.
Induction of diabetes
At 6 weeks of age, mice were treated with streptozotocin
(STZ; Sigma-Aldrich Corporation, St. Louis, MO, USA).
Animals were injected with five consecutive daily doses
of STZ dissolved in citrate buffer (55 mg/kg, pH 4.5) via
the intraperitoneal route. One week after the first dose,
blood glucose levels were assessed using a glucometer. The
criterion of two consecutive glucose levels >250 mg/dL
was used to indicate diabetes. If glucose levels were
<250 mg/dL, then the mice received two additional doses
of STZ. Both diabetic and non-diabetic mice were
followed for 2 months to allow the diabetes to stabilize be-
fore femoral artery ligation.
Femoral artery ligation
The hair on the abdominal wall and pelvis and the upper
legs was shaved using an electronic shaver after the
mouse was under anesthesia with 4% isoflurane induc-
tion and 1% maintenance. The skin was prepped using
povidone-iodine (5%) followed by three alcohol preps. A
skin incision was made on the upper thigh of the mouse.
The inguinal ligament and the upper half of the femoral
artery are exposed in both legs. On the left leg, thefemoral artery was ligated with two sterile 8/0 non-
absorbable silk sutures below the inguinal ligament proxi-
mally and just above the bifurcation into the superficial
and deep femoral arteries distally. The vascular bundle on
the right leg was isolated without further intervention.
The skin incision was closed with sterile 5/0 nylon suture.
Preparation of radiotracer
Monoclonal anti-RAGE antibody was developed as pre-
viously described [16]. For 99mTc labeling, the antibody
was fragmented into F(ab’)2 using a pepsin digestion kit
(Pierce, Rockford, IL, USA). Approximately 1 mg of the
F(ab’)2 was conjugated with 5 M excess of diethylene
triamine pentaacetic acid (DTPA; Sigma). The reaction
mixture was incubated at room temperature for 30 min
followed by overnight dialysis at 4°C in phosphate-
buffered saline (PBS) (0.15 M NaCl, 0.05 M NaHCO3,
pH 7.6). To 50 to 100 μg of anti-RAGE F(ab’)2, 50 μg of
SnCl2 in 0.1 N HCl (flushed in N2 gas for 15 min) and
30 to 50 mCi 99mTc were added and incubated at room
temperature for 45 min. The 99mTc-labeled antibody
fragments were separated from free 99mTc using a PD-10
column pre-equilibrated with 0.1 M PBS (pH 7.4). The
mean radiopurity was 97 ± 0.5% by instant thin-layer
chromatography. Control non-specific mouse IgG F(ab’)2
was similarly conjugated with DTPA for 99mTc labeling
as described above.
In vivo imaging
Five days after femoral artery ligation, each mouse was
anesthetized with isofluorane (4% to induce, 1% to main-
tain) for placement of a jugular vein catheter (Braintree
Scientific, Braintree, MA, USA) and was injected with
0.41 ± 0.12 mCi 99mTc-anti-RAGE F(ab’)2 or control non-
specific mouse IgG F(ab’)2 and 4 to 5 h later (blood pool
clearance) underwent single-photon emission computed
tomography/computed tomography (SPECT/CT) imaging
on nanoSPECT/CT (Bioscan, Washington, DC, USA).
A topogram (sequence of 2D side view X-ray projec-
tions) was used to determine the axial scan range for
SPECT and CT imaging. CT images were acquired with
an integrated CT scanner using an X-ray tube at 45 kVp
and an exposure time of 1,000 ms per view. Following
CT acquisition, helical SPECT scans were acquired using
dual-headed detectors, each outfitted with nine pinhole
apertures. Each pinhole has a diameter of 1.4 mm with
each collimator providing a transaxial field-of-view (FOV)
of 30 mm and an axial FOV of 16 mm, extendable
through helical scanning to 270 mm. SPECT data were ac-
quired with the following parameters: step and shoot rota-
tion, 30° step in 360° rotation using 24 projections, 60 s
per projection, 256 × 256 frame size with 1.0-mm pixels,
and 140 keV with 10% energy window. The obtained pro-
jection data were reconstructed by ordered subsets
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iteration number set to 16 and 8, respectively, and a voxel
size of 300 μm and SPECT and CT datasets fused.
At the completion of in vivo imaging, mice were eu-
thanized by an intraperitoneal injection of pentobarbital
(100 mg/kg).
Image analyses
The scans were reconstructed and processed using
InVivoScope software (Invicro, Boston, MA, USA). On
serial 5-voxel-thick transverse sections from below hip
joints to distal hind limbs, regions of interest were drawn
and activity in mCi summed for each limb and subse-
quently divided by the injected dose (ID).
Gamma well counting
The anterior tibialis muscles were dissected and weighed,
and the radioactivity was determined in a gamma well
counter (Wallac Wizard 1470, PerkinElmer, Waltham,
MA, USA) and expressed as the percentage of injected
dose per gram (%ID/g) of tissue. The radiotracer activity
in the samples was corrected for background, decay time,
and tissue weight.
Histopathology
Three sets of explanted tibialis anterior muscles per
group were fixed in 10% formalin for 48 h. Three serial
sections (5 μm thick) per experiment from paraffin-
embedded blocks were processed for hematoxylin and
eosin (H&E) for morphological evaluation and immuno-
histochemical analysis.
Serial sections were deparaffinized and rehydrated fol-
lowed by quenching of endogenous peroxidase activity
with 0.3% hydrogen peroxide. Slides were then incubated
overnight with monoclonal anti-RAGE antibody (50 μg/ml).
Slides were incubated for 30 min with biotinylated sec-
ondary antibody. To identify capillary sprouting, staining
was performed with biotinylated Griffonia (Bandeiraea)
simplicifolia isolectin I (1:50; Vector Laboratories, Burlin-
game, CA, USA). Sections were treated for 30 min with
VECTASTAIN ABC reagent (Vector Laboratories). Color
reaction was visualized with 3′,3′-diaminobenzidine (DAB
substrate kit, Dako, Mississauga, Ontario, Canada) and
counterstained with Gill’s hematoxylin solution. All brown
staining areas were counted for each of the three sections
for both the left and right anterior tibialis muscles for each
experiment, and averaged RAGE and lectin staining were
quantified as area staining positive for the brown chromo-
gen per 100× field.
Images were captured using a digital camera mounted
on a Nikon microscope (Nikon Co., Tokyo, Japan) and
analyzed using Image-Pro Plus software (Media Cyber-
netics Inc., Bethesda, MD, USA).Immunofluorescence
Dual fluorescent confocal microscopy studies were per-
formed to identify the cell source of RAGE staining.
Muscle sections (5 μm thick) were deparaffinized in xylene
and incubated with monoclonal mouse anti-RAGE F(ab')2
(50 μg/ml; Texas Red) and co-stained with endothelial
cells (FVIII, 1:200; fluorescein isothiocyanate), macro-
phages (Mac-3, 1:50; fluorescein isothiocyanate), and
myocytes (anti-sarcomeric actin, 1:50; fluorescein isothio-
cyanate). The images were examined using a confocal
fluorescence microscope (Nikon) and SPOT imaging
software (Diagnostic Instruments, Inc., Sterling Heights,
MI, USA).
Statistical analysis
Continuous variables were expressed as mean ± standard
deviation. Normality was assessed using the Sharpiro-
Wilk W test. Equality of variances was assessed using
Levene’s test. Comparisons between groups were made
using paired two-tailed Student’s t test or the Mann–
Whitney U test, as appropriate with P < 0.05 denoting
significance. Correlation was assessed using the Pearson
product–moment correlation coefficient. Statistical analy-




Summed uptake of the probe on coronal slices from
SPECT/CT scans following injection of 99mTc-anti-RAGE
F(ab’)2 5 days after left femoral artery ligation showed
greater uptake of the tracer in the left (ischemic) limbs of
diabetic mice compared to the probe uptake in the ische-
mic limbs of non-diabetic mice injected with 99mTc-anti-
RAGE F(ab’)2 or in the ischemic limb of mice injected
with non-specific IgG F(ab’)2 (control probe) (Figure 1A).
The quantitative tracer uptake as %ID in the diabetic left
(ischemic) limb (1.2 ± 0.44 × 10−3) was significantly higher
than the uptake in the non-diabetic left limb (0.49 ±
0.40 × 10−3; P = 0.0007) (Figure 1B). Tracer uptake in the
diabetic right (non-ischemic) limb (0.82 ± 0.33 × 10−3)
was also significantly higher than the uptake in the non-
diabetic right limb (0.40 ± 0.14 × 10−3; P = 0.0004).
Ex vivo gamma counting
The higher uptake of 99mTc-anti-RAGE F(ab’)2 in the
diabetic left (ischemic) limbs was confirmed by ex vivo
gamma well counting (Figure 2). The mean tracer up-
take in the diabetic left limbs as %ID/g (0.046 ± 0.017)
was significantly higher than the uptake in the non-
diabetic left limbs (0.019 ± 0.012; P = 0.02) or limbs of
mice injected with non-specific control IgG F(ab’)2
(0.005 ± 0.0007; P = 0004) (Figure 2A). The mean count























Figure 1 Scan results. (A) Representative coronal slices from SPECT/CT scans following injection of 99mTc-anti-RAGE F(ab’)2 5 days after left FAL for a
WT diabetic mouse (left), WT non-diabetic mouse (center), and WT non-diabetic mouse injected with non-specific mouse IgG F(ab’)2 (right). (B) Bar
graph shows quantitative RAGE uptake from scans in hind limbs for WT diabetic (left set of bars) and WT non-diabetic (right side set of bars) 5 days
after FAL. Each bar represents average ± SD. DM, diabetes mellitus; NDM, non-diabetes mellitus; FAL, femoral artery ligation; WT, wild type.
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for non-diabetic (1.66 ± 0.65; P = 0.01) or mice injected
with control non-specific IgG F(ab’)2 (0.95 ± 0.15; P =
0.001) (Figure 2B).
Histopathology
Immunohistopathology supported the scan findings. Ex-
amples of anterior tibialis muscle tissue sections stained
for H&E and RAGE are shown in Figure 3. The average
RAGE staining, determined as percent area staining
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Figure 2 Ex vivo well counting for both hind limbs. (A) Bars represent v
the blue bars represent the right hind limbs. (B) Bars represent values for thdiabetic left limbs (21.3 ± 6.2%) was significantly greater
than that for the contralateral right limb (5.6 ± 4.3%; P =
0.02) or non-diabetic left limbs (7.6 ± 5.6%; P = 0.04).
Dual fluorescent staining identified RAGE co-localization
predominantly with myocytes within the ischemic muscle
(Figure 4).
Serial sections were also stained for capillary sprouting
(biotinylated Griffonia (Bandeiraea) simplicifolia isolectin I).
Lectin staining for the non-diabetic left limbs (1.25 ±
0.36%) was significantly higher than that for the diabetic
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Figure 3 Histological findings. Serial sections from ischemic (L) diabetic and non-diabetic limbs. H&E staining is shown on the left and RAGE







Figure 4 Dual immunofluorescent staining for cells expressing RAGE in ischemic limb sections. Sites of RAGE expression were shown to
be mainly myocytes based on co-localization of RAGE (Texas Red) with anti-sarcomeric actin (green, fluorescein isothiocyanate) in the merged
image. Co-localization of RAGE with macrophages (Mac-3, fluorescein isothiocyanate) was also seen in the merged image. Areas in yellow
represent co-localization. EC, endothelial cells; Mac, macrophages.




















Figure 5 Lectin staining. Representative tissue sections obtained from ischemic hind limbs stained with H&E and lectin. Scale bar = 40 μm.
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We demonstrated that the effect of diabetes on RAGE
expression can be imaged and quantified in a murine fem-
oral artery ligation model of limb ischemia using a RAGE-
targeting 99mTc-labeled probe and SPECT/CT imaging.
The quantitative expression of RAGE from the scans cor-
related with the degree of suppression of angiogenesis
measured from lectin staining on immunohistological sec-
tions of the ischemic and non-ischemic limbs. We have
previously shown that the effect of diabetes to suppress
angiogenesis in a similar live animal model can be imaged
with 99mTc-HYNIC-RGDs targeting ανβ3 integrin in ische-
mic limbs of diabetic mice with femoral artery ligation
compared to non-diabetic mice [15]. The results of this
current study show the potential feasibility of imaging and
quantifying in living subjects another important biological
signal in the development of peripheral arterial disease.
RAGE is a 35 kDa polypeptide of the immunoglobulin
superfamily that is a multiligand receptor shown to play
an important role in vascular disease [2-11]. This receptor
is constitutively expressed in low levels on smooth muscle
cells and endothelial cells in vascular walls [4]. RAGE
binds ligands that induce expression and activation of sig-
naling pathways important in promoting inflammation
and reducing vascular reactivity. These ligands include ad-
vanced glycation endproducts (AGEs), S100/Calgranulin
proteins, high-mobility group box 1 protein (HMGB1),
and oxidized LDL. Ligand-RAGE binding activates intra-
cellular pathways that generate reactive oxygen species, re-
duce nitric oxide availability, promote monocyte andleukocyte chemotaxis, and increase cytokine secretion
[4-7]. Our finding of higher quantitative uptake of our
radiolabeled probe in the contralateral (non-ischemic)
limbs of the diabetic compared to the non-diabetic non-
ischemic limbs supports the ability of this imaging tech-
nology to document the effect of diabetes alone to induce
RAGE expression in the peripheral arteries.
As occlusive lower extremity lesions progress, flow re-
serve is lost and there is further progression to resting
hypoxia. In the non-diabetic limb, in response to tissue
hypoxia, VEGF is released locally via the HIF-1a pathway
and stimulates angiogenesis through multiple mechanisms
that include increased proliferation and decreased apop-
tosis of endothelial cells and chemoattraction of monocytes
into the ischemic tissue [8,9]. In diabetes, this normally
adaptive response to hypoxia is blunted. RAGE has been
shown to have a major mechanistic role in this maladaptive
response by reducing VEGF mRNA and by inducing a de-
fect in signal transduction of VEGF in monocytes which re-
duces their response to chemotactic protein-1, resulting in
fewer monocytes in the tissue to stimulate angiogenesis
[11,12,17]. While the murine femoral artery ligation hind
limb ischemia model lacks the component of occlusive
proximal arterial disease found in humans, it is currently a
standard small-animal model used to study the molecular
biology of limb ischemia [18]. The results of the experi-
ments reported in this manuscript concur with the molecu-
lar biology reported for RAGE and angiogenesis pathways.
Clinical imaging tests for lower extremity ischemia focus
on detection of blood flow reduction and/or presence and
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tial for a molecular imaging approach targeting the biology
of peripheral artery disease to demonstrate the extent of
small-vessel disease. Two important targets in this disease
process are RAGE expression and its effect on the angio-
genic responses to tissue hypoxia. A pathology study
reported by Rigghaler et al. in 1995 documented promin-
ent enhancement of endothelial RAGE expression in
small- and medium-sized arteries in patients with occlu-
sive peripheral vascular disease both with and without dia-
betes [20]. While large vessels such as the aorta can be
visualized at necropsy, smaller arteries require multiple
sampling for histology and quantification is subject to
sampling error. With this limitation, it is more difficult to
assess the total extent of receptor expression. An in vivo
molecular imaging approach which can visualize an entire
limb has the potential to provide generalized vascular ex-
pression of RAGE in live subjects both as a research tool
and as a non-invasive marker for the effect of therapies di-
rected at suppressing RAGE to improve the symptoms
and prognosis for PAD.
Experimental studies suppressing RAGE ligands have
shown improvement in angiogenic response to limb is-
chemia [13,14]. Drugs that inhibit ligands that bind
RAGE have been tried in humans, but each has limita-
tions regarding efficacy or untoward side effects [21].
Aminoguanidine, a small hydralazine-like compound,
blocks AGE formation but did not advance in clinical
trials due to adverse side effects in diabetics attributed
to sequestration of pyridoxal and vitamin B6 deficiency
[21]. Another approach is to block AGEs with soluble
RAGE to prevent binding to RAGE and suppress initi-
ation of the signaling pathways [22]. Soluble RAGE
made from the extracellular two thirds of the receptor
was developed for mouse studies, but limited quantities
are currently available. A humanized rat monoclonal anti-
RAGE antibody that antagonizes RAGE interactions with
multiple ligands was shown to be a potent protector
against the toxic effects of sepsis [23]. Because of the mul-
tiple ligands binding RAGE and its importance in a
spectrum of diseases, there is a clear impetus to develop-
ing better RAGE-suppressing drugs. A non-invasive tool
that can quantify RAGE expression in vivo would be use-
ful in monitoring the effects of such drug on the molecu-
lar signals.
Conclusions
The results of these experiments document the feasibil-
ity of imaging and quantifying RAGE expression in the
hind limbs of a relevant mouse model of limb ischemia
and show the effect of diabetes to increase the expres-
sion and thereby reduce angiogenesis. Future directions
include combined imaging protocols targeting both
RAGE and either ανβ3 integrin and/or VEGF to morecompletely map the biology of limb ischemia in the live
animal, to follow the mice longer after occlusion, and to
monitor the functional consequences of flow reduction
using ultrasound techniques.
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